“I am excited to join C4T to oversee the clinical development of the company’s targeted protein degraders,” said Dr. Crystal. “C4T is positioned to lead discovery and development efforts for a new class of medicines with the potential to offer meaningful clinical benefit for patients who currently have no effective treatment options.”
“Dr. Crystal’s deep understanding of the science of targeted protein degradation, coupled to his proven clinical leadership and understanding of the patient community, will be instrumental to advancing C4T’s pipeline,” said Andy Phillips, Ph.D., President and CEO of C4T.
Marc Cohen, C4T’s Executive Chairman added “Adam expands C4T’s leadership team at an important stage of the company’s growth as we move to bring this new mode of medicine into the clinic over the next two years.”
Prior to joining C4 Therapeutics, Dr. Crystal was at the Novartis Institutes for BioMedical Research, where he led several early development programs in oncology. Before Novartis, Adam was a medical oncologist at Massachusetts General Hospital researching resistance mechanisms to targeted therapies. He completed his internal medicine training at Massachusetts General Hospital and his fellowship in medical oncology at the Massachusetts General Hospital Cancer Center and the Dana Farber Cancer Institute. Adam holds an M.D., as well as a Ph.D. in Neuroscience, from the University of Pennsylvania.
About C4 Therapeutics
C4 Therapeutics (C4T) is pioneering a new class of small-molecule drugs that selectively target disease-relevant proteins for degradation using the innate machinery of the cell. This targeted protein degradation approach has the potential to treat a range of diseases and offers advantages over traditional drugs, such as potential to minimize drug resistance, de-risked starting points, high potency and specificity. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com.
MacDougall Biomedical Communications